Research Study

A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD [DYNAGITO]
Principal Investigator 
Jeremy D. Road

Overview

Body Locations and Systems 
COPD
ClinicalTrials.gov# 
NCT02296138
Status 
Closed to Recruitment
Study Start/End 
Feb 1, 2015 to Feb 28, 2017
Locations 
Diamond Health Care Centre
Name/Title 
Lena Legkaia, Research Coordinator
Phone 
604-875-4111 ext.69831
Email Address 
lena.legkaia@vch.ca
Purpose of Study 

The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in patients with severe to very severe COPD

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.